HGEN

Ifabotuzumab | KB004

Glioblastoma Multiforme (GBM)

Phase 1

Exp Date

TBD

Amp Volatility Score

Catalyst Info & Data Links

TITLE: Ifabotuzumab for Glioblastoma Multiforme (GBM) / Solid Tumors

  • ClinicalTrial.gov (NCT03374943): A Trial of KB004 in Patients With Glioblastoma


WHAT IS THE NEXT CATALYST EVENT?

  • TBD


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA

PRESS RELEASES

POSTERS

COMPETITORS

MECHANISM OF ACTION / RATIONALE

  • Ifabotuzumab is a non-fucosylated IgG1K antibody targeting EphA3 receptor

Updated by HC

#HGEN, #Ifabotuzumab, #KB004, #Glioblastoma_Multiforme, #GBM

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

Do failures of IL-6 blockers r...

Do you agree that today's announcement of the failure of #RHHBY's IL-6 blocker #Actemra to treat COVID [https://www.roche.com/media/releases/med-cor-2020-07-29.htm] and the prior failure of #REGN's #K...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon